For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Secukinumab - Psoriasis
PAD Profile : Secukinumab - Psoriasis
Traffic Light Status
Status 1 of 1.
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Adalimumab
- Etanercept
- Infliximab
- Ustekinumab (Psoriasis)
- Apremilast
- Ixekizumab
- Brodalumab (Psoriasis)
- Guselkumab (Psoriasis)
- Tildrakizumab
- Certolizumab pegol
- Risankizumab
Other Indications
- Ankylosing spondylitis
- Psoriatic arthritis
- Any paediatric use
- Non-radiographic axial spondyloarthritis
- Hidradenitis suppurativa
Additional Documents
Committee Recommendations
The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed the reviewed and updated high cost immunomodulator psoriasis treatment pathway.
The Surrey Heartlands ICS Area Prescribing Committee have agreed an update of the Psoriasis High Cost immunomodulator Drug Treatment Pathway.
The pathway has been updated following guidance from the Regional Medicines Optimisation Committee in May 2020, in relation to the sequential use of biologic medicines. The agreed process and associated documentation is saved here https://surreyccg.res-systems.net/PAD/Search/DrugConditionProfile/6549
The PCN support the use of Secukinumab as a treatment option for treating moderate to severe plaque psoriasis in line NICE TA 350